Scarica l'app Stockscreener
45.27
4.55%
1.97
Dopo l'orario di chiusura:
45.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$43.30
Aprire:
$43.32
Volume 24 ore:
1.16M
Relative Volume:
1.03
Capitalizzazione di mercato:
$3.60B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-7.6212
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-11.43%
1M Prestazione:
-6.76%
6M Prestazione:
-7.48%
1 anno Prestazione:
+44.59%
Intervallo 1D:
$43.32
$45.99
Intervallo di 1 settimana:
$43.17
$51.97
Portata 52W:
$30.41
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
45.27 | 3.44B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript - Insider Monkey
What makes PTC Therapeutics Inc. stock price move sharplyROI Verified Swing Candidates - thegnnews.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Cut to Hold at Wall Street Zen - MarketBeat
FY2025 Earnings Forecast for PTCT Issued By Leerink Partnrs - MarketBeat
Earnings Update: PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Momentum Screeners Rank PTC Therapeutics Inc. in Top 5 TodayCommunity Strategy With High Win Rate Backtested - metal.it
PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownHere's Why - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $79.00 at Wells Fargo & Company - MarketBeat
PTC Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 10,739 Shares - MarketBeat
PTC Therapeutics: Pioneering a New Growth Cycle in Rare Disease Innovation - AInvest
PTC Therapeutics and the Launch of Sephience™: A Catalyst-Driven Play in Rare Disease Innovation - AInvest
PTC Therapeutics Enters Rights Satisfaction Agreement - The Globe and Mail
PTC Therapeutics Announces Q2 2025 Financial Results - The Globe and Mail
PTC Therapeutics outlines Sephience $1B-plus U.S. revenue potential following FDA and EU launches - MSN
Federated Hermes Inc. Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Beat Expectations But Shares Still Dropped - Finimize
PTC Therapeutics price target lowered to $70 from $72 at Baird - TipRanks
Transcript : PTC Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
PTC Therapeutics stock price target raised to $63 from $60 at RBC Capital - Investing.com Canada
PTC Therapeutics stock price target raised to $56 from $52 at TD Cowen - Investing.com Canada
RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating - MarketScreener
PTC Projects Confidence In Sephience Launch With Royalty Buyback - insights.citeline.com
Earnings call transcript: PTC Therapeutics beats Q2 2025 EPS expectations By Investing.com - Investing.com Nigeria
Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating - MarketScreener
Ptc Therapeutics 2025 Q2 Earnings Strong Performance as Net Income Surges 34.6% - AInvest
PTC Therapeutics and Evolent Health Receive Bullish Sentiments from Analysts - AInvest
PTC Therapeutics: A Strategic Pivot to Sephience and the Path to Sustained Growth - AInvest
PTC Therapeutics Q2 Loss Narrows, Revenue Declines; Sets Full-Year Revenue Guidance - 富途牛牛
PTC Therapeutics Inc (PTCT) Q2 2025 Earnings Call Highlights: St - GuruFocus
PTC Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Reports Q2 2025 Financial Results - TipRanks
PTC Therapeutics Q2 2025 Earnings Preview - MSN
PTC Therapeutics: Q2 Earnings Snapshot - Chron
PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions - TipRanks
PTC Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PTC Therapeutics (PTCT): A Strategic Assessment of Growth Catalysts and Profitability Potential Post-Sephience Approval - AInvest
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Citizen Tribune
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
PTC Therapeutics reports Q2 EPS (83c), consensus ($1.06) - TipRanks
PTC THERAPEUTICS Earnings Results: $PTCT Reports Quarterly Earnings - Quiver Quantitative
PTC Therapeutics Inc Surpasses Revenue Estimates with $179 Million in Q2 2025; Sephience Launch Marks Strategic Milestone - GuruFocus
PTC Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com Canada
PTC Therapeutics: Pioneering Rare Disease Innovation with a Diversified Pipeline and Strategic Growth Catalysts - AInvest
JPMorgan raises PTC Therapeutics stock price target to $68 on Sephience demand - Investing.com Canada
PTC Therapeutics: Strategic Shift and Robust Financials Drive Buy Rating with $68 Target by 2025 - TipRanks
PTC Therapeutics Earnings Preview: Analysts Expect $-1.07 EPS, Historical Performance and Stock Performance - AInvest
PTC Therapeutics Earnings Preview - 富途牛牛
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):